Fatigue News and Research

RSS

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

$Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma$

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.

8 Dec 2009

JAK2 inhibitor can control myelofibrosis, report researchers

A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Geisinger installs catheter-based cardiac assist device, Impella 2.5

A minimally invasive, catheter-based cardiac assist device - the Impella 2.5 - is credited with saving the life of 86-year-old Rose Lombardo of Hazleton. Grandmother to seven and great-grandmother to another 12, Rose was "at death's door" after suffering concurrent heart attacks, according to her daughter, Gabriella Norgard.

8 Dec 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Seattle Genetics, Inc. today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma.

8 Dec 2009

Non-clinical data of CK-2017357 presented by Cytokinetics

Cytokinetics, Incorporated announced today that both a poster and an oral presentation summarizing non-clinical data regarding CK-2017357, a novel fast skeletal troponin activator, were presented at the 5th Cachexia Conference, organized by the Society on Cachexia and Wasting Disorders, being held December 5-8, 2009 in Barcelona, Spain.

8 Dec 2009

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).

8 Dec 2009

Regular sexual activity can help improve the overall health in men

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released the top ten reasons regular sexual activity can help improve men’s overall health. From decreased blood pressure to more restful sleep, sexual activity is essential for maintaining bodily functions as well as overall health and well-being.

7 Dec 2009

CDC announces the start of National Influenza Vaccination Week

Today the Centers for Disease Control and Prevention (CDC) announced the start of National Influenza Vaccination Week. While the week was designed to highlight the importance of flu vaccinations, it also brings to light the importance of taking additional steps to keep you and your family healthy during the peak cold and flu season of December, January and beyond.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

Deal time? Key Senate Dems meet on public option in health bill

Politico: "President Barack Obama will meet Sunday with Senate Democrats on Capitol Hill, as a group of moderate and liberal senators weighed a new public option compromise in hopes of striking a deal by early in the week.

6 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

ARC workers protest that unfair labor practices can endanger donor and blood safety issues

Teamsters who work at American Red Cross (ARC) Blood Services facilities in Philadelphia went on strike this morning to protest unfair labor practices and problems with working conditions at these facilities that could imperil the safety of donors and the integrity of the blood supply, not to mention the wellbeing of employees.

3 Dec 2009

Fatigue News and Research

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

JAK2 inhibitor can control myelofibrosis, report researchers

Geisinger installs catheter-based cardiac assist device, Impella 2.5

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Non-clinical data of CK-2017357 presented by Cytokinetics

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Regular sexual activity can help improve the overall health in men

CDC announces the start of National Influenza Vaccination Week

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

ImmunoGen reports encouraging clinical data of IMGN901

Deal time? Key Senate Dems meet on public option in health bill

Positive final data from Phase 2 study of ISTODAX presented

New treatment options for leukemia and myeloproliferative disorders introduced

FDA approves once-daily SEROQUEL XR Extended Release Tablets

ARC workers protest that unfair labor practices can endanger donor and blood safety issues

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News